News

Bayer AG faces a significant new legal setback as a Georgia jury has ordered the German pharmaceutical and agrochemical giant to pay approximately $2.1 billion (€1.9 billion) in damages over claims

AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00

Die Bristol-Myers Squibb Aktie zeigt sich derzeit in solider Verfassung. Der Kurs des Biopharmazie-Riesen kletterte auf 61,04 USD (Stand: 22. März 2025), was einem Anstieg von 1,01% zum Vortag

Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous

Biomarin Pharmaceutical recently presented compelling new data for its key medications VOXZOGO and PALYNZIQ at the American College of Medical Genetics and Genomics annual meeting, sparking investor

Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears

Quest Diagnostics, a leading provider of diagnostic information services, experienced a significant 4.75% decline on the New York Stock Exchange following disappointing long-term growth projections

Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per

Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide

Incyte Corporation is poised for significant market growth following positive results from two pivotal Phase 3 trials for Povorcitinib, its oral JAK1 inhibitor targeting Hidradenitis suppurativa

Die Teleflex Aktie verzeichnete am vergangenen Freitag einen moderaten Anstieg von 0,80% und erreichte damit einen Kurs von 126,50 EUR. Diese positive Entwicklung steht im Kontrast zur schwachen

Novartis shares experienced a notable decline on Friday at the Swiss SIX exchange, falling 0.7 percent to close at 96.25 CHF. The pharmaceutical stock opened at 96.52 CHF before touching a daily low

Roche's stock has displayed a mixed performance in recent trading sessions. On Thursday afternoon, shares initially gained 0.5 percent to reach 304.70 CHF on the SIX Swiss Exchange, even touching a

Eli Lilly's stock is facing pressure following a strategic partnership announcement between Swiss pharmaceutical giant Roche and Danish firm Zealand Pharma. The deal, valued at up to $5.3 billion

Healthcare giant Johnson & Johnson is demonstrating remarkable resilience in a volatile market environment. Currently trading at $165.68, the stock has established itself as a defensive asset

Merck, known internationally as MSD, has significantly strengthened its position in the American market with the opening of a new vaccine production facility in Durham, North Carolina. The

Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid

Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share in an all-cash transaction. The deal values 2seventy bio at approximately

Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based

Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination